Credit: Shutterstock. A regulatory decision is expected in January 2024. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for STS101 (dihydroergotamine ...

SAN DIEGO — A single dose of a dihydroergotamine mesylate (DHE) nasal powder formulation appears to quickly and significantly reduce migraine pain, results of a new phase 3 study showed. DHE is an ...

The recommended dose of Atzumi is 5.2 mg, the contents of 1 nasal device, administered into 1 nostril. The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine) nasal powder for ...

The Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for STS101 (dihydroergotamine [DHE] nasal powder) for the acute treatment of migraine with or ...

The FDA approved dihydroergotamine (DHE) nasal powder (Atzumi) 5.2 mg to treat acute migraine with or without aura in adults, Satsuma Pharmaceuticals announced Wednesday. The product is the only DHE ...

09 June 2011 - Malvern, UK - Laser diffraction particle size analysis, already widely used in the characterization of a variety of OINDPs (orally inhaled and nasal drug products) is proving its value ...

AUSTIN, Texas — Sustained freedom from pain and the most bothersome migraine symptom was achieved in more patients treated with investigational STS 101 compared with placebo, according to a study ...

The collaboration is in line with Orexo's (ORXOY) strategy to broaden the use of its powder-based drug delivery technology AmorphOX ®. Abera is a developer of mucosal vaccines and has several ...

Please provide your email address to receive an email when new articles are posted on . The FDA on Wednesday approved the first nasal glucagon powder for the emergency treatment of severe hypoglycemia ...

The Food and Drug Administration just approved a needle-free treatment for hypoglycemia for people with diabetes. The FDA said it approved Baqsimi nasal powder as emergency treatment of severe ...

DURHAM, N.C., Oct. 30, 2024 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company, and its corporate parent, Shin Nippon Biomedical ...

Atzumi™ (dihydroergotamine(DHE)) nasal powder is the first and only DHE nasal powder for the acute treatment of migraine with or without aura in adults in an easy-to-use, easy-to-carry device. Atzumi ...